MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder, Vladimir Makarov, Taha Merghoub et al. · New England Journal of Medicine · 2014 · 4.4K citations · Full text

Medicine, Immunology, Oncology +17

Genomic Classification of Cutaneous Melanoma

Rehan Akbani, Kadir C. Akdemir, Bülent Arman Aksoy et al. · Cell · 2015 · 3.2K citations · Full text

Medicine, Genetics, Oncology +14

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

Medicine, Oncology, Pharmacology +16

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

Medicine, Oncology, Pharmacology +7